Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Short term Debt: 2020-2021

  • BridgeBio Pharma's Short term Debt was N/A to $3.6 million in Q1 2021 from the same period last year, while for Mar 2021 it was $3.6 million, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2020, which is N/A change from last year.
  • Per BridgeBio Pharma's latest filing, its Short term Debt stood at $3.6 million for Q1 2021, which was up 150.07% from $1.5 million recorded in Q4 2020.
  • In the past 5 years, BridgeBio Pharma's Short term Debt registered a high of $3.6 million during Q1 2021, and its lowest value of $1.5 million during Q4 2020.
  • In the last 2 years, BridgeBio Pharma's Short term Debt had a median value of $2.6 million in 2020 and averaged $2.6 million.